Menu Search
Equities

Equasens SA

PHF:DUS

Equasens SA

Actions
  • Price (EUR)43.50
  • Today's Change-0.80 / -1.81%
  • Shares traded200.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 07:12 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Equasens SA is formerly known as Pharmagest Interactive SA is a France-based company. The Company is engaged in publishing and integration of software packages intended for pharmacies, hospitals, health establishments, laboratories, retirement homes and health professionals. Its activity is distributed in publishing and integration of software packages for pharmacies, publishing of IT solutions for health and medico-social establishments and development of solutions and infrastructure for e-Health. It provides software packages for managing databases, information, stocks, orders, electronic care sheets, etc. It offers publishing and integration of software packages for retirement homes, hospitals and care homes (software for managing admissions, invoicing, tracking collections and accounting, care monitoring, stewardship management, etc.);

  • Revenue in EUR (TTM)219.79m
  • Net income in EUR47.05m
  • Incorporated1996
  • Employees1.24k
  • Location
    Equasens SA5 Allee de Saint-CloudVILLERS LES NANCY 54600FranceFRA
  • Phone+33 383159595
  • Fax+33 383159805
  • Websitehttps://equasens.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		EQS:PAR since
announced		Transaction
value
SARL DigipharmacieAnnounced02 Jan 202402 Jan 2024Announced-28.64%--
Data delayed at least 15 minutes, as of Nov 14 2024 12:24 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.